TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma

TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma

Abstract Objective Multiple myeloma is a haematological malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Development of resistance and minimal residual disease remain challenging in the treatment of multiple myeloma. Transforming growth factor-β activated kina...

Full description

Bibliographic Details
Main Authors: Erling Håland, Ingrid Nyhus Moen, Esten N. Vandsemb, Kristian K. Starheim
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Research Notes
Subjects:
Multiple myeloma
TAK1
Haematological malignancy
5Z-7
NG25
Online Access:https://doi.org/10.1186/s13104-022-06237-3

Internet

https://doi.org/10.1186/s13104-022-06237-3

Similar Items